CSMG Technologies Forms Cosmetic Surgery Subsidiary under Live Tissue Connect

CORPUS CHRISTI, Texas--(BUSINESS WIRE)--CSMG Technologies, Inc., (OTCBB: CTUM), a technology management company, announced today the company has added a procedure specific, Cosmetic Surgery subsidiary to the five medical procedure specific subsidiaries wholly owned by its Live Tissue Connect, Inc. (“LTC”) subsidiary .

“The Aesthetic market is one of the fastest growing markets today. This LTC division will be focused on the development of disposable instruments and associated electrosurgical generators to allow the fusing/welding together of tissue. Preliminary lab and clinical work on cosmetic epidermis tissue is on-going and shows great promise.”

The new subsidiary for cosmetic surgery (Aesthetic Tissue Welding, ATW), is added to the five already exiting subsidiaries established in May 2007 for:

• Gynecology and General Surgery (GSG Medical Group)
• Orthopedics & Arthroscopy (Orthopedic Tissue Sciences)
• Colon Rectal Surgeries (Colorectal Connection Management)
• Pulmonary/lung (Pulmonary Sealing Sciences)
• Urology (Urological Tissue Welding)

Donald S. Robbins, President and CEO of CSMG, said, "We believe this cosmetic surgery subsidiary will be one of the most profitable and successful subsidiaries of LTC. All six of our LTC subsidiaries have strong market opportunities, but cosmetic surgery is often elective surgery, thus attracting a higher premium for procedures where faster healing and little or no scarring is concerned. We will continue to isolate procedures and products for specific medical specializations.”

“Now that final development of our first series of disposable instruments and electro surgery generator are almost completed, and having filed with the US FDA for our duct and vessel sealer, we are attracting interest from many qualified medical device companies and distributors who want to represent, license or market some area of the LTC product. Each of the LTC wholly owned subsidiaries represent a unique manufacturing, marketing or licensing opportunity. We are excited over this unique opportunity and I believe this approach adds considerable value to the company,” added Mr. Robbins.

LTC's Frank D'Amelio added, "The Aesthetic market is one of the fastest growing markets today. This LTC division will be focused on the development of disposable instruments and associated electrosurgical generators to allow the fusing/welding together of tissue. Preliminary lab and clinical work on cosmetic epidermis tissue is on-going and shows great promise."

CSMG owns the technology and exclusive world rights to the live tissue bonding device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and commercialization of the platform technology.

LTC has almost completed hand instruments, electrocautery generator and other electrosurgery components for the duct and vessel sealing system, meeting FDA and European CE Mark requirements, respectively.

About CSMG Technologies' Tissue Welding/Bonding Technology

The LTC tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matter in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues.

Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 8,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominoplasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S., Australian, Canadian and European Union patents have been issued, and additional U.S. and foreign patents are pending, all owned by LTC.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG is focused on two primary subsidiaries, Live Tissue Connect, Inc. and landfill gas processing.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to and http://www.csmgtechinternational.com/contact_information.html and fill-in information.

Safe Harbor Statement

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.